Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.07. | EXACT Therapeutics AS: EXACT Therapeutics announces grant of core patent in the U.S. | - | Oslo Børs | ||
24.06. | Exact Therapeutics AS: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer | 138 | GlobeNewswire (Europe) | OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.... ► Artikel lesen | |
13.06. | EXACT Therapeutics AS: EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 | 1 | Oslo Børs | ||
EXACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.06. | EXACT Therapeutics AS: Primary insider notification | 1 | Oslo Børs | ||
04.06. | EXACT Therapeutics AS - Information regarding voting at the Annual General Meeting 2025 | 1 | Oslo Børs | ||
28.05. | EXACT Therapeutics AS - Notice of Annual General Meeting 2025 | - | Oslo Børs | ||
20.05. | Exact Therapeutics AS: EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer | 280 | GlobeNewswire (Europe) | These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapyIn the patients who had a response to chemotherapy, ACT-treated... ► Artikel lesen | |
14.05. | EXACT Therapeutics AS: EXACT Therapeutics announces grant of key patent covering non-invasive delivery of pharmaceuticals to the brain | - | Oslo Børs | ||
07.05. | EXACT Therapeutics AS: EXACT Therapeutics announces grant of key patent in Japan | - | Oslo Børs |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TARSUS PHARMACEUTICALS | 40,140 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
EVOTEC | 7,658 | +3,49 % | ÜBERNAHMEFANTASIE! Barrick Mining, Evotec, Desert Gold Aktie | Wie die hohen Preise hält sich auch die Übernahmefantasie im Goldsektor. Als Kandidat wird immer wieder Desert Gold genannt. Mit der spannenden Akquisition in Westafrika hat der Explorer diversifiziert... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 35,950 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,590 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,950 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
SOLID BIOSCIENCES | 7,070 | 0,00 % | Solid Biosciences gets FDA fast track status for heart disease therapy | ||
SUMMIT THERAPEUTICS | 26,740 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
EDGEWISE THERAPEUTICS | 13,950 | 0,00 % | Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating | ||
KINIKSA PHARMACEUTICALS | 30,400 | +12,43 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
ADMA BIOLOGICS | 18,260 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
SALARIUS PHARMACEUTICALS | 0,989 | 0,00 % | Pre-market Movers: DURECT Corporation, Salarius Pharmaceuticals, ScanTech AI Systems, AIM ImmunoTech, Bakkt Holdings | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green DURECT Corporation (DRRX) is up over 267% at $2.03.
Salarius... ► Artikel lesen | |
BIONTECH | 97,00 | +0,52 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
UPSTREAM BIO | 13,970 | -2,58 % | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | ||
QIAGEN | 44,335 | +0,11 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,930 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen |